Enable Accessibility
Enable Accessibility
Better Health,
Brighter Future
Newsroom
Careers
Investors
Patients
HCPs
Worldwide
Who We Are
About Takeda
How can we do more for our patients?
Everything at Takeda starts with this question.
Learn more
Company Information
Company Facts & Japan offices
History
Worldwide Offices
Executive Leadership
Positions
Takeda Global Headquarters
Design Concept
Where we work
Corporate Philosophy
Corporate Governance
Values and Corporate Governance
Board of Directors
Nomination Committee and Compensation Committee
Audit and Supervisory Committee and Internal Audit
Our Management
Charters and Reports, etc.
Risk & Crisis Management
Global Ethics & Compliance / Global Code of Conduct
Transparency Disclosures
EFPIA Disclosure Code Reports
Patient Group Disclosures
Contact Us
Celebrating the grand opening of Takeda Global Headquarters
LEARN MORE
What We Do
Our Business
We will become a global, values-based, R&D-driven, biopharmaceutical leader
Learn more
Research & Development
Science Stories
Our Pipeline
Clinical Trials
R&D Partnering
Supporting the Scientific Community
Areas of Focus
Oncology
Rare Diseases
Neuroscience
Gastroenterology
Plasma-Derived Therapies
Vaccines
Alliances & Partnerships
Takeda Digital Ventures
Our Products
Manufacturing
Innovation Story
Access to Medicines
Our Approach and Our Position
Hear from Patients
Driving Impact with Partners
Pre- Approval Access
Suppliers
Sustainable Procurement
Supplier Code of Conduct
Supplier Diversity
Third Party Risk Management
Supplier Registration Process via Ariba Commerce Cloud
Responsible Procurement
Purchase Orders and Invoices
Takeda Supplier Solutions Portal
Contact us
T-CiRA
About T-CiRA
Leaders Message
What we do
Portfolios
Projects
Inside T-CiRA
Research Achievements
Future of iPSC
We focus on our core therapeutic areas.
LEARN MORE
Our Stories
Our Stories
Two centuries. Countless innovations. One vision.
Learn more
All Stories
Corporate Responsibility
Takeda's CSR
Takeda is committed to addressing the world’s biggest challenges to sustainable development over the long term.
LEARN MORE
Programs in Action
Takeda Chair in Global Child Health
Takeda Initiative for the Global Fund
Global CSR Program
Apply for Funding
Frequently Asked Questions
Leaders Driving Change
Purpose led-Sustainability at Takeda
Patient
People
Planet
Governance
Reporting on Sustainability
TAKEDA LIFE THEATER, Embark on a journey of discovery inside the human body!
LEARN MORE
HOME
Newsroom
Global News Releases
Share:
Newsroom
Global News Releases
Statements
In the News
Featured Topics
Corporate Materials
Social Media
Global News Releases
Enter
All
Last 12 months
2022
2021
2020
2019
2018
2017
2016
December 2022
December 9, 2022
12/9/2022
Takeda to Present Data at 64th American Society of Hematology (ASH) Annual Meeting, Demonstrating Commitment to Patients with Hematologic Cancers and Other Blood Diseases
December 8, 2022
12/8/2022
Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved for Use in European Union
November 2022
November 22, 2022
11/22/2022
Takedas Biologics License Application BLA for Dengue Vaccine Candidate TAK-003 Granted Priority Review by US Food and Drug Administration
November 17, 2022
11/17/2022
Phase 3 Trial of ICLUSIG® (ponatinib) Met Primary Efficacy Endpoint in Frontline Ph+
November 11, 2022
11/11/2022
European Commission EC Approves LIVTENCITYTM maribavir
October 2022
October 27, 2022
10/27/2022
Takeda Delivers Strong FY2022 H1 Results and Raises Full-Year Forecast
October 20, 2022
10/20/2022
Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy
October 14, 2022
10/14/2022
Takeda Receives Positive CHMP Opinion Recommending Approval of Dengue Vaccine Candidate in EU and Dengue-Endemic Countries
October 13, 2022
10/13/2022
Takeda to Hold 2nd Quarter Earnings Call on October 27
1
2
3
4
5
TOP
Close
